羅欣藥業(002793.SZ):獨家引進韓國HK inno.N替戈拉生注射劑 加碼P-CAB
格隆匯6月24日丨羅欣藥業(002793.SZ)宣佈,公司子公司山東羅欣藥業集團股份有限公司(簡稱“山東羅欣”)與韓國HK inno.N Corporation(原CJ HealthCare Corporation公司)於2021年6月23日簽署了《許可協議》,就引進替戈拉生注射劑產品達成協議,山東羅欣將獲得該產品在中國的獨家開發、生產和商業化的權利。
替戈拉生是鉀離子競爭性酸阻滯劑類藥物(Potassium-Competitive Acid Blockers,P-CAB),其抑制酸分泌的作用機制為競爭性結合壁細胞內H+/K+-ATP酶(質子泵)的鉀離子結合部位。與傳統抑酸藥物質子泵抑制劑(PPI)不同,P-CAB可直接抑制H+/K+-ATP酶,而無需在強酸環境下活化。而且,無論H+/K+-ATP酶活化與否,P-CAB均可與之結合。
替戈拉生注射劑主要用於治療胃食管反流、上消化道出血和預防應激性胃黏膜損傷等,具有起效快、作用時間長、酸性條件下穩定、可同時抑制激活和靜息狀態質子泵等特點。
替戈拉生注射劑在全球範圍內尚無產品上市。根據IQVIA數據,目前抑酸類藥物注射用質子泵抑制劑(PPI)2020年度在我國境內的銷售金額總計為127.7億元(按招標價計算)。
公司在消化領域一直具備較強的市場競爭力,2015年10月,山東羅欣與HK inno.N Corporation達成協議,獲得替戈拉生片在中國境內獨家開發、生產及商業化權益,目前替戈拉生片1類新藥上市申請已獲得受理。
該次引進的替戈拉生注射劑產品,體現了公司在該領域持續深耕和佈局的決心及優勢,進一步豐富了公司產品管線和儲備,提升了拓展業務的能力,彰顯了公司科技創新能力和核心競爭力,符合公司戰略發展需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.